THE SCIENCE
Keratin is a primary component of human skin and plays a key role in the wound healing process. ProgenaMatrix harnesses this power in a novel, bio-inspired matrix.
HOW IT WORKS
ProgenaMatrix leverages the natural properties of human keratin to support every phase of wound healing.
Keratinocyte Activation
Human keratin stimulates keratinocyte activation and migration, essential for re-epithelialization.
Collagen Synthesis
Promotes fibroblast activation and collagen synthesis for wound bed granulation.
Immune Modulation
Modulates the immune response to create an environment conducive to healing.
Protease Resistance
Keratin resists protease degradation, allowing for longer effective treatment periods.
Clinical Evidence
A peer-reviewed study published in the International Wound Journal evaluated
ProgenaMatrix in Wagner grade one non-healing diabetic foot ulcers.
Healing rate (bi-weekly)
Healing rate (weekly)
Mean area reduction
Patients in trial
Armstrong et al., International Wound Journal, 2024. DOI: 10.1111/iwj.70029
In Vitro Research
Keratinocyte Migration
Preclinical studies demonstrate that human keratin drives keratinocyte migration in vitro and accelerates wound closure in vivo.
In Vivo Results
Scratch assay studies demonstrate that keratinocytes migrate and proliferate into empty areas more quickly in the presence of human keratin, supporting the mechanism of accelerated re-epithelialization.
In Vitro Results
In a delayed-healing diabetic mouse model, human keratin matrix accelerated wound closure when compared to other advanced biomaterial products, supporting the clinical findings in chronic wound management.
Published Research
Across Wound Types
ProgenaMatrix has published clinical evidence across venous leg ulcers and pressure ulcers, in addition to the multi-center diabetic foot ulcer trial above. Download the full papers below.
VLU
Difficult-to-Heal Venous Leg Ulcers
Prospective case series of 6 patients with chronic VLUs: 59% median wound-area reduction at 4 weeks, with 33% achieving complete closure in the same window.
Ellis S, et al. ePlasty. 2023;23:QA10.
VLU
Human Keratin Matrix Accelerates Healing of Venous Ulcers
Retrospective case series of 13 patients (16 VLUs): 88.9% complete healing in smaller VLUs and 71% area reduction in very large (>200 cm²) VLUs.
Koullias G, Ramey-Ward AN. Journal of Wound Care. 2024;33(11):842–848. DOI: 10.12968/jowc.2024.0248
PU
Human Keratin Matrix in Post-Acute Pressure Ulcer Care
Bayesian real-world study of 161 matched pressure ulcers: 54.3% healing rate with HKM+SOC vs 33.8% with SOC alone. 99.4% posterior probability of benefit (RR ~1.6).
Tunyiswa Z, et al. International Journal of Tissue Repair. 2026. DOI: 10.63676/vt5yx857
More information
Learn more about ProgenaMatrix and the science behind the keratin matrix.
Using ProgenaMatrix with UltraMIST Therapy
Pairing Revyve Antimicrobial Gel + ProgenaMatrix
Real Limb Salvage and Large Wound Results
Two-Week Dwell Time
510(k) Cleared & Indicated for Pressure Ulcers
Retrospective Research and Why Human Keratin Works
Wound Care Practice?
Contact us to learn more about ProgenaMatrix and
how it can benefit your patients.
ProgenaMatrix is distributed by Venture Medical, LLC.